Complement activation as a therapeutic target and clinical biomarker for Parkinson's disease

帕金森氏症是澳大利亚第二大常见的神经系统疾病，但目前还没有减缓疾病进展的治疗方法。我们的研究正在调查大脑内的炎症是帕金森病的主要诱因。我们将在帕金森氏症患者中研究这种炎症途径，并将在帕金森氏病的动物模型中测试一种新型抗炎药，以确定一种新的治疗方法来减少疾病病理。

Parkinson’s disease is the second most common neurological disease in Australia, yet there is no treatment to slow disease progression. Our study is investigating inflammation within the brain as a major contributing factor in Parkinson’s disease. We will examine this inflammatory pathway in human patients suffering from Parkinson’s, and will test a novel anti-inflammatory drug in animal models of Parkinson’s disease, in order to identify a novel treatment to reduce disease pathology.